Hi Thaliat,
That's because that's what a Phase I study is always about. There can be secondary efficacy endpoints/notes. but Phase I studies are always about safety.
Also, importantly, that's the name and official title of the study.
Check out the link below for a study and have a look at the Primary, Secondary and Other Outcome measures.
Primary are always safety and dosage in phase I
https://classic.clinicaltrials.gov/ct2/show/NCT05346484
Understanding Cancer, page-7
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.001(1.69%) |
Mkt cap ! $439.1M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.1¢ | 5.8¢ | $1.072M | 18.07M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 85851 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 335299 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.1¢ |
Change
0.001 ( 2.37 %) |
||||
| Open | High | Low | Volume | ||
| 5.9¢ | 6.1¢ | 5.8¢ | 7197252 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| IMU (ASX) Chart |